| Clinical Trial Name | Clinical Trial Full Title | Principal Investigator | Project site status | Clinical trials gov number |
|---|---|---|---|---|
| (Alkermes) ALK4230-A101 | A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors | Hirte, Dr Hal | Open to recruitment | NCT02799095 |
| (BI) 1381.1 / REFMAL 473 | An open-label, Phase I trial to determine the maximum-tolerated dose and investigate safety, pharmacokinetics, and efficacy of BI 754091 in patients with advanced solid tumours | Hirte, Dr Hal | Open to recruitment | NCT02952248 |
| (BMS) CA021002 | A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 (anti-ICOS mAb) Alone or in Combination with Nivolumab or Ipilimumab in Patients with Advanced Solid Tumors | Hotte, Dr Sebastien | Open to recruitment | NCT03251924 |
| (BMS) CA209848 / CheckMate 848 | A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) | Hotte, Dr Sebastien | Open to recruitment | NCT03668119 |
| (CCTG) IND.228 | A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare Tumours | Hirte, Dr Hal | Open to recruitment | NCT02879162 |
| (Esperas) ESPS-001 | A Phase 1b/2a Two-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination with Gemcitabine in Patients with Advanced or Metastatic Cancer | Hirte, Dr Hal | Open to recruitment | NCT02632448 |
| (Fusion) FPX-01-01 | A Phase 1 Study of [225Ac]-FPI-1434 Injection in Patients with Advanced Solid Tumours | Juergens, Dr Rosalyn | Open to recruitment | NCT03746431 |
Find a Trial
Contact Us